Bank of Industry Healthcare Fund
The Bank of Industry (BOI) Healthcare Fund is an on-lending intervention scheme for the Healthcare sector developed as part of the pro-active measures to improve quality of Healthcare by enhancing access to funding across the sector.
The initiative was developed to provide funding to indigenous pharmaceuticals, hospitals, clinics, diagnostic centres and other business in the healthcare value chain, to enable them increase capacity to meet the increasing demand for healthcare.
Features
LOAN LIMIT
N5 billion Naira
Pricing
- Interest rate: 15% per annum
Loan Tenor
-
Term Loan - Maximum of 5 years including 6 months moratorium on principal and interest.
-
Working Capital - Maximum of 2 years including 3 months moratorium on principal and interest
Eligible Participants
- Healthcare product manufacturers
- Healthcare service providers/ medical facilities
- Pharmaceutical/medical products distribution and logistics services
- Other human healthcare service providers
Benefits
- This initiative provides long-term, low cost finance to facilitate the development of the Nigerian healthcare sector.
- It will improve access to affordable credit for indigenous pharmaceutical companies for expansion and to encourage compliance with the WHO Good Manufacturing Practice.
- The scheme will contribute to the overall development of the Nigerian Healthcare system.
-
Features
-
Pricing
-
Loan Tenor
-
Eligible Participants
-
Benefits
LOAN LIMIT
N5 billion Naira
- Interest rate: 15% per annum
-
Term Loan - Maximum of 5 years including 6 months moratorium on principal and interest.
-
Working Capital - Maximum of 2 years including 3 months moratorium on principal and interest
- Healthcare product manufacturers
- Healthcare service providers/ medical facilities
- Pharmaceutical/medical products distribution and logistics services
- Other human healthcare service providers
- This initiative provides long-term, low cost finance to facilitate the development of the Nigerian healthcare sector.
- It will improve access to affordable credit for indigenous pharmaceutical companies for expansion and to encourage compliance with the WHO Good Manufacturing Practice.
- The scheme will contribute to the overall development of the Nigerian Healthcare system.